Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1983 1
1984 4
1998 1
2001 1
2002 3
2003 1
2004 1
2005 7
2006 4
2007 2
2008 1
2010 4
2011 2
2012 1
2014 2
2015 2
2016 5
2017 3
2018 2
2019 4
2020 3
2021 6
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
A difficult diagnosis?
Babu KG, Lokanath D, Kumar P, Harita S, Nimit N, Girish R, Bapsy PP. Babu KG, et al. Among authors: harita s. Lancet Oncol. 2002 Jun;3(6):332. doi: 10.1016/s1470-2045(02)00772-6. Lancet Oncol. 2002. PMID: 12107019 No abstract available.
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
Kuribayashi T, Ohashi K, Nishii K, Ninomiya K, Tsubata Y, Ishikawa N, Kodani M, Kanaji N, Yamasaki M, Fujitaka K, Kuyama S, Takigawa N, Fujimoto N, Kubota T, Inoue M, Fujiwara K, Harita S, Takata I, Takada K, Okawa S, Kiura K, Hotta K. Kuribayashi T, et al. Among authors: harita s. J Cancer Res Clin Oncol. 2024 Feb 12;150(2):89. doi: 10.1007/s00432-024-05618-4. J Cancer Res Clin Oncol. 2024. PMID: 38347279 Free PMC article.
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
Ichihara E, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Ichihara E, et al. Among authors: harita s. Cancer Immunol Immunother. 2021 Jan;70(1):101-106. doi: 10.1007/s00262-020-02662-0. Epub 2020 Jul 10. Cancer Immunol Immunother. 2021. PMID: 32648165 Free PMC article.
59 results